An independent in-depth analysis proposing adjusted Global Initiative on Asthma Step 1-2 treatment suggestions.

The Global Initiative on Asthma (GINA) strategy included major changes for the treatment of mild asthma in the 2020 version that are even taken to the next level in 2021, leaving a preferred track with only rescue therapy with inhaled corticosteroid and formoterol (ICS-FORM) for steps 1-2 in 12+ years old. It has been questioned how solid the evidence behind these recommendations is. We decided to independently conduct an in-depth analysis of published evidence based on a comprehensive evaluation of original articles and related appendices and publications, including quality of evidence and risk of bias per article. We first defined the major asthma treatment goals and proceeded to review how these were met in publications referenced in the main asthma guidelines. For patients with GINA (2021) Step 1 characteristics, the analysis supports GINA's decision to avoid SABA monotherapy and to prefer ICS-FORM rescue with an alternative ICS rescue every time a SABA is used for ≥12 years, even though evidence is extrapolated from step 2 patients. For 6- to 11-year-olds, we propose to consider ICS-FORM rescue as an alternative, as its use has been approved in this age group, be it not as rescue medication. For patients with GINA 2021 Step 2 characteristics, our proposal slightly differs from GINA 2021. We propose to continue avoiding the separate use of SABA, using ICS rescue whenever a fast-acting bronchodilator is taken (even with ICS maintenance). Also, the superiority of ICS-FORM rescue over classical step 2 treatment is not uniform and year-long experience is lacking. Consequently, for now, both treatment options seem equal: ICS-FORM rescue or ICS maintenance with SABA (+ICS) rescue. For 6- to 11-year-olds, ICS rescue every time a SABA is used has the advantage of lower total ICS dose; as alternative we suggest ICS-FORM rescue. The best treatment option depends on patient characteristics and treatment goals. Recommendations should be reviewed as soon as new evidence becomes available.

Células inflamatorias en la secreción nasal y citocinas proinflamatorias Th1, Th2, Th17 y reguladoras en el suero de pacientes con leishmaniasis cutánea Americana / Inflammatory cells in the nasal secretion and serum pro-inflammatory Th1, Th2, Th17 and regulatory cytokines from American cutaneous leishmaniasis patients

En la forma mucocutánea (LCM) y cutánea (LCL) de la leishmaniasis, se genera una respuesta inflamatoria cuyos mediadores (células y citocinas) se han involucrado en la severidad de las úlceras y en el daño tisular observado en estos pacientes, particularmente en los LCM. Por ello, nos propusimos identificar los grupos celulares predominantes en la secreción nasal de pacientes con LCL y LCM, y relacionarlos con citocinas proinflamatorias y reguladoras. Evaluamos en pacientes LCL (n=20), LCM (n=14) y 20 individuos sanos: a) La cuantificación de tipos de leucocitos en "frotis" de secreción nasal, úlceras cutáneas y sangre periférica teñidos con Giemsa empleando microscopía óptica, b) Concentraciones séricas de IL-8, IL-4 e IL-10 por citometría de flujo (CBA array) e IFN-γ, TNF-α e IL-17 por ELISA. El grupo celular predominante en la secreción nasal de pacientes con LCM fueron los neutrófilos (80,7%) y escasos eosinófilos (0,6%), comparados con los LCL y controles, en los que no se observaron estas células. Mientras que los "frotis" de las ulceras de los LCL presentaron 45,3% de neutrófilos y 43% de linfocitos. En contraste, en sangre periférica, de los pacientes se observó un incremento de neutrófilos y linfocitos junto a una frecuencia significativa de monocitos (LCM: 5,3; LCL: 6,3%) y eosinófilos (LCM: 8,2%; LCL: 5,2%). Todo esto sugiere la participación de los neutrófilos en la inmunopatogénesis en la LCM. Adicionalmente, se demostró una mayor (P=0,03) concentración sérica de IL-8 en los pacientes con LCL (18,5ρg/mL) y LCM (18,2ρg/mL) respecto a los individuos sanos, sugiriendo que esta citocina promueve el reclutamiento de neutrófilos al sitio de infección en los LCM, mientras que en los LCL contribuyen junto con los linfocitos T CD4+ de la subpoblación Th1 y productores de IFN-γ, en la activación de mecanismos leishmanicidas.

In mucocutaneous (MCL) and cutaneous (LCL) leishmaniasis, the inflammatory mediators (cytokines and cells) have been associated with ulcers severity and tissue damage observed in these patients, particularly in MCL. Therefore, we decided to identify the predominant cell groups in the nasal secretion of LCL and MCL patients, and related pro-inflammatory and regulatory cytokines. It was evaluated in LCL (n = 20), MCL patients (n = 14) and 20 healthy volunteers: a) Differential leukocyte count by optical microscopy performed in: smear of a runny nose, skin ulcers and peripheral blood dyed with Giemsa, b) serum levels of IL-8, IL-4 and IL-10 using cytometric bead array (CBA) assay and IFN-γ, TNF-α and IL-17 by ELISA. In MCL patients, neutrophils (80.7%) were the most abundant cellular group in nose secretion, followed by a small amount of eosinophils (0.6%) compared to the LCL and controls, where no such cells were observed. In contrast, in peripheral blood from ACL patients were observed an abundant amount of neutrophils and lymphocytes together with a significant frequency of monocytes (MCL:5.3%; LCL: 6.3%) and eosinophils (MCL:8.2%; LCL:5.2%). While the smear from skin ulcers of LCL patients showed 45.3% of neutrophils and 43% lymphocytes. All of these indicate that neutrophils might play a role in the MCL immunopathogenesis. Moreover, an increased serum levels of IL-8 (P=0.03) were found in LCL (18.5ρg/mL) and MCL (18.2ρg/mL) patients, suggesting that this cytokine promotes the recruitment of neutrophils to the infection site in MCL; while in LCL patients may contribute with CD4 + Th1 (IFN-γ) cells in the activation of leishmanicida mechanisms.

Uso del ivermectin en el tratamiento de la escabiosis / Use of the invermectin in the treatment of the scabies

Evaluaciones clínicas y parasitológicas, durante un periodo de 16 semanas, permitieron demostrar la curación del 93,3 por ciento de un total de 30 pacientes escabiósicos adultos de ambos sexos, tratados con una sola dosis oral de ivermectin de 200 mg/kg de peso corporal. La efectividad y ausencia de efectos colaterales significativos observados sugieren a los autores simplicidad, aceptabilidad y eficacia del ivermectin en el tratamiento de la escabiosis humana